The Core Issue: Failure to Warn Patients of Severe Risks The central argument in the GLP-1 lawsuits is that manufacturers like Novo Nordisk and Eli Lilly knew, or should have known, about the risk of severe side effects like stomach paralysis and bowel obstruction but failed to adequately warn doctors and patients
Mounjaro/Zepbound (tirzepatide), approved dual GLP-1/GIP agonist for type 2 diabetes and obesity Recent Highlights: In April 2026, the FDA approved orforglipron (Foundayo), making it one of the first oral GLP-1 pills that can be taken any time of day and that has no food or water restrictions
Neurological symptoms such as numbness, tingling, burning, or weakness may occur when the tumor compresses or invades nearby nerves
To date, no clinical trial data exists for semaglutide use in PWS
Cognitive impairments In male POS-offspring, both vitamin PP (P56-85) [106] and Leucine (P20-60) [105] led to improvement in ES-induced cognitive impairments in the ORT and the BM at an unknown age [106] and in the MWM at 2 months of age [105]